Skip to Content
 
Center for International Blood and Marrow Transplant Research

P-6157

Main Content

Return to Listing

Blood | 2025

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: A joint CIBMTR and EBMT analysis.

Perales MA, Awan FT, Boumendil A, Patel J, Castagna L, Angelucci E, Finel H, Kulagin A, Glass B, Corradini P, Herrera AF, Blaise D, Kharfan-Dabaja MA, Halahleh K, Ahmed S, Martinez C, Giebel S, Montoto S, Jones RJ, Ahmed N, Lynch RC, de Lima MJ, Shadman M, Sauter CS, Ahn KW, Hamadani M, Bazarbachi A, Sureda A

PubMed
PMID: 40623049

Abstract
Related Articles

CIBMTR Study #: LY20-02

Working Committee: Lymphoma

Dataset Files:
This dataset was collected by the Center for International Blood and Marrow Transplant Research (CIBMTR) which is supported primarily by the Public Health Service U24CA076518 from the National Cancer Institute; the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; 75R60222C00011 from the Health Resources and Services Administration; N00014-23-1-2057 and N00014-24-1-2057 from the Office of Naval Research; NMDP; and the Medical College of Wisconsin. By downloading the dataset files below, you agree to the Terms and Conditions.
I agree to the Terms and Conditions; Download Dataset

I agree to the Terms and Conditions; Download Data Dictionary